Zobrazeno 1 - 10
of 78
pro vyhledávání: ''
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-7 (2021)
BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-7 (2021)
Background The cancer burden is rising rapidly worldwide, and it annually causes about 8.8 million deaths worldwide. Due to chemical drugs’ side effects and the emergence of resistance, the development of new green drugs has received much attention
Autor:
Ryosuke Shirakawa, Shintaro Kinugawa, Takashi Yokota, Shingo Takada, Naoya Kakutani, Takaaki Furihata, Hideo Nambu, Satoshi Maekawa
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-10 (2021)
BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-10 (2021)
Background Doxorubicin (DOX) is widely used as an effective chemotherapeutic agent for cancers; however, DOX induces cardiac toxicity, called DOX-induced cardiomyopathy. Although DOX-induced cardiomyopathy is known to be associated with a high cumula
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-9 (2021)
BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-9 (2021)
Background There are no reports on the incidence of chronic mercury poisoning in a large population in China. This study investigated the epidemiology, clinical manifestations, treatment, and follow-up of Chinese patients with chronic mercury poisoni
Autor:
Takashi Seto, Masashi Kimura, Y. Kogure, Kenichi Suzuki, Toshinobu Hayashi, Mototsugu Shimokawa, Tomomi Takiguchi, Takeshi Koike, Satoru Shimizu, Makoto Nishio, Reiko Matsui, Tomohiko Harada, Kimiko Fujiwara, Naoyuki Nogami, Hirotsugu Kenmotsu, Koichi Goto, Hiroyasu Kaneda
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-10 (2020)
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-10 (2020)
Background Of patients receiving moderate emetic risk chemotherapy (MEC), 30–90% experience chemotherapy-induced nausea and vomiting (CINV); however, the optimal antiemetic treatment remains controversial. Methods In this multicenter, prospective,
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-9 (2020)
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-9 (2020)
Background The indoleamine 2, 3-dioxygenase (IDO) inhibitor 1-methyl-tryptophan (1-MT) is currently being used in clinical trials in patients with relapsed or refractory solid tumors by inhibiting tumor immune escape. A greater understanding of IDO a
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-8 (2020)
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-8 (2020)
Background Hyponatremia, a marker of disease severity and prognosis, has been associated with various clinical factors and drug use, especially diuretics. Methods This observational prospective cohort study enrolled patients hospitalized at the Unive
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-10 (2020)
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-10 (2020)
Background Flavonoids, which existed nearly in all fruits and vegetables, are considered as a class of plant-secondary metabolites with a polyphenolic structure and have properties with health-improving potential. Yet, not so many experimental focus
Autor:
Kazumi Nishino, Hanako Kuhara, Kei Kunimasa, Toru Kumagai, Motohiro Tamiya, Madoka Kimura, Takako Inoue
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-4 (2020)
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-4 (2020)
Background Pulmonary sarcomatoid carcinoma is a rare non-small-cell lung cancer (NSCLC) subtype with a poor prognosis. In the phase III PACIFIC study, durvalumab significantly improved progression-free survival and overall survival versus placebo, in
Autor:
Eduardo de França Damasceno, Miguel N. Burnier, Ruiz Simonato Alonso, Marcelo Palis Ventura, H. P. Solari
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-7 (2020)
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-7 (2020)
Background The study aimed to evaluate and compare the leukocyte chemotactic activities of various brimonidine tartrate (BT) eye drop formulations. Methods A 96-well dot-blot platet using a Boyden-style well was used to study the chemotactic effects
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-7 (2020)
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-7 (2020)
Background Although recent studies using experimental models of ischemic brain injury indicate that systemically-administered β1-blockers have potential protective effects on the cerebrovascular system, the precise mechanisms remain unclear. In addi